ERBB2 and breast adenocarcinoma: Additional molecular classifiers included three brain metastases derived from HER2+ breast adenocarcinomas, one from a melanoma with the activating mutation BRAF V600E (Fig EV2R), and one from a gastro‐esophageal cancer without known oncogenic drivers sensitive to HSP90 inhibition (Fig EV2S).